Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

d explanation is lack of specificity of Trasylol®.

TXA and EACA are lysine analogs that function as competitive inhibitors of plasminogen activation and, at much higher concentrations, noncompetitive inhibitors of plasmin.  These agents are considered to be safer but less effective than Trasylol®. While TXA is approximately 10 times more potent than EACA, it is associated with a fourfold increase over EACA in the risk of seizures.  Further, a study demonstrated that patients administered TXA required more transfusion product than patients who were administered Trasylol®, resulting in significantly higher overall transfusion-related costs for patients treated with the less expensive, generic agent TXA.  

Omeros' proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein. This selectivity could provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immunological side effects.

About Omeros' Antifibrinolytic Program

Omeros is developing a series of novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma. Omeros' agents are designed to selectively inhibit plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein, important regulators of the coagulation cascade. These agents could provide a superior replacement for the antifibrinolytic agents Trasylol® (aprotinin), tranexamic acid and epsilon aminocaproic acid. The selectivity of Omeros' agents may provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immuno
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Legislation backed by the drugstore lobby (H.R. ... of 2014") championing so-called "any willing pharmacy" mandates ... of lower cost preferred pharmacy networks and increase ... 10 years, according to new research from The ... Association (PCMA). The drugstore lobby targets ...
(Date:7/22/2014)... 2014 Research and Markets  has announced ... report to their offering. ... to diagnose, monitor, and assess medical conditions, diseases, or ... outcomes for earlier and more targeted treatment. These tests ... accurate results. This kind of diagnostics provides early detection ...
(Date:7/22/2014)... BiologicTx ® today announced their participation ... Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching software, ... at the Miami Transplant Institute, located at Jackson Memorial ... Kidney Paired Donation (KPD) is an option ... transplant with one another due to incompatible blood types ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3
... , SAN DIEGO , Feb. 4 ... and income results for the quarter ended December 31, 2009 . Revenue ... 23% increase (a 17% increase on a constant currency basis) over the quarter ... 2009 , income from operations was $57.9 million and net income ...
... , , ATLANTA , Feb. 4 Given ... Health (HITECH) Act, Elekta has expanded its STRATEGIQ™ Services ... incentives available from the federal government. These incentives will be issued ... are able to demonstrate meaningful use. , Part of the 2009 ...
Cached Medicine Technology:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 2ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 3ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 4ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 5ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 6ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 7ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 8ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 9ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009 10Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 2Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 3
(Date:7/22/2014)... Rochelle, NY -- New guidelines on cholesterol treatment and ... double the risk of dying from atherosclerotic cardiovascular disease ... do women with a similar risk profile (based on ... The implications of this finding for when and how ... Editorial in Journal of Men,s Health , a ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Beryl ... and third annual Institute Scholar Program. These offerings reinforce ... the patient experience in healthcare and the need for ... The grant and scholar programs are intended ... , Value of focusing on the patient experience ...
(Date:7/22/2014)... The Pennsylvania judge overseeing hundreds ... in the Philadelphia Court of Common Pleas won’t ... cases alleging the medication caused plaintiffs to develop ... In an Order dated July 18, 2014, Judge ... certify the matter for an immediate appeal to ...
(Date:7/22/2014)... July 22, 2014 The park is ... the Kendalltown Homeowners Association, Inc., made a ... residential community with the purchase of playground equipment from ... located in beautiful Miami Florida, and is a 475-unit ... of the surrounding landscape has created a tropical paradise ...
(Date:7/22/2014)... TUESDAY, July 22, 2014 (HealthDay News) -- One of ... of a psychiatric disorder has uncovered 83 new sites ... The findings, made by an international team of ... variants linked to the disorder to 108. ... used as a test to predict who will or ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... to lack a particular protein in the brain have ... they say, for exploring the hereditary causes of deafness ... provides an entry point for gaining new insight into ... the protein, says the team, led by scientists at ...
... ATSI ) is looking forward to its ... of Thoracic Surgeons (STS). The event runs January,28-30, ... one of the year,s,key gatherings of cardiovascular surgeons ... ), ATS Medical continues to broaden its ...
... Rochester,Medical Corporation (Nasdaq: ROCM ) will announce quarterly ... The Company will then,hold a quarterly conference call to ... p.m. central standard time (5:00 p.m. eastern time)., ... be accessed at,Rochester Medical,s website at http://www.rocm.com . ...
... PRINCETON, N.J., Jan. 24 The final ... Care Resources,provides a thorough and candid explanation of ... short on delivering solutions to address,the healthcare system,s ... consensus of the New Jersey Hospital Association, the,state,s ...
... Personalizing ones nutrition for maximum health benefits is becoming ... help health professions learn more about this trend at ... Nutrition" is the theme for the 35th annual Texas ... The event, at the Rudder Tower, is from 8 ...
... on healthy living, healthy aging, healthy ... communities, ... million investment in three initiatives that will help,Silicon Valley become the healthiest ... strides in achieving the goals,of healthy living, healthy aging, and healthy communities ...
Cached Medicine News:Health News:Deafness and seizures result when mysterious protein deleted in mice 2Health News:Deafness and seizures result when mysterious protein deleted in mice 3Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 2Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 3Health News:Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008 2Health News:NJHA: State Report Provides Thorough Examination of Hospital Fiscal Woes 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 3
Cushing-landolt bi-valve speculum for trans-sphenoidal hypophysectomie....
Hardy pituitary spoon, bayonet, malleable....
... the T.L.I.F. market as the premium banana-shaped implant. ... history and the amazing success of the Devex ... to be king of the jungle amongst T.L.I.F. ... in height. The footprint is 28 mm x ...
... The Stackable Cage System provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon Fiber Polymer cages that are ... patient needs. The Peek Carbon Fiber Reinforced ...
Medicine Products: